Pantoprazole and Docetaxel for Men With Metastatic Castration-Resistant Prostate Cancer

Inclusion Criteria: * Age ≥18yrs * ECOG performance status ≤2 * Histologically or cytologically confirmed adenocarcinoma of the prostate * Clinical or radiological evidence of metastatic disease * Disease progression while receiving androgen deprivation therapy with an increase in PSA of 25% or greater over nadir value measured on 3 consecutive occasions at least 1 week apart * Antiandrogen therapy must have been stopped at least 4 weeks prior to start of trial treatment (6 weeks in the case of bicalutamide or nilutamide)if there was a reduction in serum PSA after this therapy was initiated * Baseline serum prostate-specific antigen (PSA)≥10ng/ml * Total testosterone \<50 ng/dL (\<1.7 nmol/L) * Adequate hematologic values: neutrophil count ≥1,500/mm3, platelet ≥100,000/mm3, hemoglobin ≥10.0 g/dl * Adequate hepatic and renal function: total bilirubin level ≤1.5 x ULN (unless secondary to documented Gilbert's disease); ALT,AST, and creatinine ≤1.5 x ULN * Ability to understand and to sign consent for the study Exclusion Criteria: * Prior treatment for prostate cancer with chemotherapy or radioisotopes * History of another cancer within the preceding five years (except basal or squamous-cell skin cancer or adequately treated superficial bladder cancer) * Known or suspected brain or leptomeningeal metastases * Symptomatic peripheral neuropathy of grade 2 or higher * Major surgery within 4 weeks of start of trial treatment * Radiotherapy to ≥25% of the bone marrow and any radiotherapy within 4 weeks of start of trial treatment * Known hypersensitivity to trial treatment or hypersensitivity to any of its components * Any concomitant drugs contraindicated for use with the trial treatment * Any serious underlying medical condition which could impair the ability of the patient to participate in the trial * Any psychological, familial, sociological or other patient related factors that might preclude compliance with the study protocol